Acarbose

Acarbose is an alpha-glucosidase inhibitor originally developed for type 2 diabetes management that has garnered significant attention in longevity research. Studies suggest the drug works by blocking carbohydrate-digesting enzymes in the small intestine, effectively reducing caloric absorption and creating a metabolic state similar to caloric restriction. Research indicates this mechanism may activate key longevity pathways including AMPK signaling and sirtuin proteins, while also promoting beneficial changes in gut microbiota composition.

Large-scale epidemiological studies have suggested associations between acarbose use and improved cardiovascular outcomes, while animal research has demonstrated significant lifespan extension in male mice. The drug's ability to reduce postprandial glucose spikes and improve insulin sensitivity may contribute to its potential anti-aging effects. Research indicates acarbose may also influence inflammation markers and oxidative stress pathways, though the clinical significance of these effects in healthy populations remains under investigation.

While generally well-tolerated, acarbose commonly causes gastrointestinal side effects including flatulence, diarrhea, and abdominal discomfort due to increased colonic fermentation of undigested carbohydrates. Studies suggest these effects often diminish with continued use and dietary adjustment. The growing body of research supporting acarbose's potential longevity benefits has led to increased off-label interest, though most clinical data comes from diabetic populations, and research in healthy individuals remains limited.